Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

COVID-19 Pandemic Anniversary + Cancer Biotech Acquisitions

COVID-19 Pandemic Anniversary + Cancer Biotech Acquisitions

FromXtalks Life Science Podcast


COVID-19 Pandemic Anniversary + Cancer Biotech Acquisitions

FromXtalks Life Science Podcast

ratings:
Length:
40 minutes
Released:
Mar 24, 2021
Format:
Podcast episode

Description

This podcast was recorded on March 15, 2021In Episode 3 of the Xtalks Life Science Podcast, the team reflects on the 1-year anniversary of the start of the COVID-19 pandemic. Ayesha explains how far we’ve come since March 2020 in terms of vaccine development, but discusses the inequities in distribution of the COVID-19 vaccines despite the establishment of the WHO’s COVAX Facility.Ayesha also discusses the four largest cancer biotech acquisitions of 2021 so far, including deals made by Agilent, Takeda and Amgen. The team discusses the potential benefits of these acquisitions and shares results of a study that found that innovation can sometimes be stalled when smaller biotech firms are absorbed by big pharmas.Read the full articles here:Reflections on the 1-Year Anniversary of the COVID-19 PandemicThe 4 Biggest Cancer Biotech Acquisitions of 2021 So FarFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social Media Twitter: @Xtalks, @XtalksMedDeviceInstagram: @XtalksFacebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured
Released:
Mar 24, 2021
Format:
Podcast episode

Titles in the series (100)

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.